Anglikang: give up the preemptive right to participate in the capital increase of Hunan Xinhe new company
Anglikang announced that according to the actual situation of the company, the company plans to give up the preemptive right to increase capital of the joint-stock company Hunan xinhexin biomedical Co., Ltd. (hereinafter referred to as "xinhexin"). After giving up the preemptive right of capital increase, the proportion of equity held by the company in xinhexin will be reduced from 12.55% to 11.16%.
This text is a result of machine translation.
Briefing Aug 01, 2022 03:11 PM
· Healthcare
Biomedical Lab Supplies Producer Acumen Bags 100 Mn of CNY in Series A Round
In-depth
Financials
WIM2022: Transcripts of Fireside Chat: China Globalization [2/2]
EqualOcean organized the WIM2022 event in New York City from July 29 to July 30, 2022. The following is the transcript of the Fireside Chat of China Globalization. Chris Marquis, Melanie Wong, and Bob Guterma are three guest speakers on this panel.
Yesterday 03:00 PM
Apr 26, 2022 12:26 PM
Apr 21, 2022 07:07 PM
Apr 18, 2022 06:30 PM
Jun 29, 2021 11:48 PM
Briefing Jun 28, 2022 04:29 PM
· Healthcare
Shuidi company has established a new pharmaceutical innovation division to further develop the pharmaceutical direction
Healthcare
Trautec Medical Raises Nearly CNY 200 Mn in Series A Financing Round
Trautec Medical, dedicated to developing and producing recombinant collagen-based biomaterials, will continue to focus on the innovation of biomaterials and strive to integrate resources from all sides.
Yesterday 06:12 PM
Healthcare
Preparation Developer Elite Pharmaceutical Nets Nearly CNY 100 Mn in Series B Round
This financing round will further promote the company's R&D and clinical trials and be used to construct new production bases. The completion of the new production base will significantly improve the application efficiency of the products independently developed by Elite and reduce the cost without reducing the capacity of the products.
Yesterday 05:56 PM
Healthcare
Aesthetic Medicine Company Tian Shi Wei Nets Tens of Millions of RMB in Series A Round
Soluble microneedle technology has received wide attention from the industry recently and is expected to be commercialized in aesthetic medicine. Tian Shi Wei gained capital preference for its R&D, mass production and quality control capabilities.
Yesterday 04:58 PM
Briefing Jun 28, 2022 03:35 PM
· Healthcare
Bai chongen: it is suggested to use the price mechanism to distribute electricity and distribute the carbon emission quota to end users
See more
Read next
Insight
In-depth
Insight
In-depth
Insight
In-depth